2394: hVIVO Secures £6m Influenza Human Challenge Trial Contract
May 07, 2026•6 min•Ep. 2394
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Watch on YouTube
Andrew Catchpole, Chief Scientific Officer of hVIVO joins Martin Luke of Vox Markets to discuss hVIVO’s newly signed £6 million influenza human challenge trial contract. Andrew explains how the study will evaluate a prophylactic antiviral treatment using hVIVO’s specialist influenza challenge model, highlighting the speed and efficiency advantages of human challenge trials, the growing focus on antiviral therapies, and why hVIVO continues to attract global clients.
For the best experience, listen in Metacast app for iOS or Android